These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 17692572)
1. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572 [TBL] [Abstract][Full Text] [Related]
2. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494 [TBL] [Abstract][Full Text] [Related]
3. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? Ahmed MS; Wong CF J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617 [TBL] [Abstract][Full Text] [Related]
5. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292 [TBL] [Abstract][Full Text] [Related]
6. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153 [TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196 [TBL] [Abstract][Full Text] [Related]
8. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Koukoulaki M; Abeygunasekara SC; Smith KG; Jayne DR Nephrol Dial Transplant; 2005 Jan; 20(1):213-6. PubMed ID: 15632353 [No Abstract] [Full Text] [Related]
9. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358 [TBL] [Abstract][Full Text] [Related]
10. Response to rituximab in patients with type II cryoglobulinemia. Bryce AH; Dispenzieri A; Kyle RA; Lacy MQ; Rajkumar SV; Inwards DJ; Yasenchak CA; Kumar SK; Gertz MA Clin Lymphoma Myeloma; 2006 Sep; 7(2):140-4. PubMed ID: 17026826 [TBL] [Abstract][Full Text] [Related]
11. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia. Korte MR; van Heerde MJ; de Man RA; Betjes MH Neth J Med; 2008 Jan; 66(1):27-30. PubMed ID: 18219065 [TBL] [Abstract][Full Text] [Related]
12. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis. Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716 [TBL] [Abstract][Full Text] [Related]
14. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. Cai FZ; Ahern M; Smith M J Rheumatol; 2006 Jun; 33(6):1197-8. PubMed ID: 16755669 [TBL] [Abstract][Full Text] [Related]
15. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Ghobrial IM; Uslan DZ; Call TG; Witzig TE; Gertz MA Am J Hematol; 2004 Dec; 77(4):329-30. PubMed ID: 15551276 [TBL] [Abstract][Full Text] [Related]
16. Rituximab for the treatment of type II mixed cryoglobulinemia. Zaja F; De Vita S; Russo D; Michelutti A; Fanin R; Ferraccioli G; Baccarani M Arthritis Rheum; 2002 Aug; 46(8):2252-4; author reply 2254-5. PubMed ID: 12209536 [No Abstract] [Full Text] [Related]